Traws Pharma completes Phase I trials of H5N1 bird flu treatment drug

Traws Pharma completes Phase I trials of H5N1 bird flu treatment drug

Source: 
Clinical Trials Arena
snippet: 

Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing H5N1 bird flu.

The randomised, placebo-controlled, double-blind trial evaluated the pharmacodynamics (PD), tolerability, pharmacokinetics (PK), and safety of escalating doses in healthy and influenza-negative adult volunteers.